Alastair Garfield, Chief Scientific Officer at Rhythm Pharmaceuticals (NASDAQ:RYTM), has sold a total of 7,763 shares of the company’s common stock on August 13, 2026, for a total value of $912,703. This sale comes amidst the company’s strong earnings and revenue growth in the second quarter of 2026. Rhythm Pharmaceuticals reported a loss of $0.73 per share, narrower than analysts’ projections of a $0.81 loss per share, and revenue reached $71.26 million, surpassing Wall Street estimates of $67.53 million. The company’s robust launch of IMCIVREE for hypothalamic obesity and continued growth in treatments for Bardet-Biedl syndrome have contributed to this positive momentum in the market. Recently, Citizens raised its price target for Rhythm Pharmaceuticals shares to $160 from $155, maintaining a Market Outperform rating, driven by high patient demand for Imcivree.
Markets
Markets